Keyword: Vir Biotechnology
Vir Biotechnology is gunning for a $100 million IPO as it looks to boost its work on infectious diseases and bring George Scangos back to Wall Street.
GlaxoSmithKline veteran Zhi Hong co-founded Brii Biosciences, a biotech with a mission to improve public health in China, in 2018.
Brii Biosciences is expanding on existing partnerships and inking a new deal with VBI Vaccines that could be worth up to $128.5 million.
Bringing innovative, clinically differentiated medicines to Chinese patients.
Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as $14 million to advance its care management technology.
Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.
Decibel Therapeutics raised $55 million in a series C round and named Vir Biotechnology CEO George Scangos as chair of its board of directors.
Alta Partners raised $130 million for its ninth venture capital fund, focusing on biotech and healthcare technology companies.
SoftBank is considering a $150 million investment in siteless trial runner Science 37, the latest in a string of biotech deals, according to reports.
Novartis Oncology head Bruno Strigini retires, Amneal poaches Allergan's Robert Stewart, plus more hirings, firings and retirings across the industry.
